Please cite this article as: YAN SY, YANG WX, LU PP, GUO XT, GUO CX, SU YN, MA LH. Complement use of Chinese herbal medicine after percutaneous coronary intervention: a prospective observational study. J Geriatr Cardiol 2022; 19(9): 696−704. DOI: 10.11909/j.issn.1671-5411.2022.09.005.
Citation: Please cite this article as: YAN SY, YANG WX, LU PP, GUO XT, GUO CX, SU YN, MA LH. Complement use of Chinese herbal medicine after percutaneous coronary intervention: a prospective observational study. J Geriatr Cardiol 2022; 19(9): 696−704. DOI: 10.11909/j.issn.1671-5411.2022.09.005.

Complement use of Chinese herbal medicine after percutaneous coronary intervention: a prospective observational study

  •  BACKGROUND Chinese herbal medicine is widely used as a complement or alternative treatment in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) in China. We compared the incidence of the major adverse cardiovascular event (MACE) of CAD patients with or without the complement use of Chinese herbal medicine after PCI.
     METHODS In this prospective, observational study that was conducted from September 2016 to August 2019 in Fuwai Hospital (China), we followed up consecutive patients who received PCI treatment for two years. MACE was defined as the composite all-cause mortality, revascularization, and myocardial infarction (MI) and was compared between those using (integrative medicine group) or those not using Chinese herbal medicine as an additional treatment to standard Western medicine, with unadjusted (Kaplan-Meier curves) and risk-adjusted (multivariable Cox regression) analyses.
     RESULTS A total of 5942 patients after PCI were enrolled in this study, and 5453 patients were included in the final analysis (4189 76.8% male; mean age: 61.9 ± 9.9% years). During the follow-ups, 2932 (53.8%) patients used only Western medicine while 2521(46.2%) patients had used Chinese herbal medicine as an additional treatment to standard Western medicine. Patients in the integrative medicine group (IM group) were older than the Western medicine group (WM group), had more females and less previous MI. The incidence of MACE was 15.3% (449/2932) in WM group and 11.54% (291/2521) in IM group. Cox regression analysis showed that cumulative incidence of MACE was 27% lower in patients of the IM group than those in WM group (hazard ratio = 0.73; 95% CI: 0.63-0.85; P < 0.0001).
     CONCLUSIONS For CAD patients after PCI treatment, complement use of Chinese herbal medicine is associated with a lower 2-year MACE incidence. Randomized prospective studies are warranted to provide higher levels of benefit evidence in these patients.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return